Reuters
23 Jul 2026, 03:55 UTC · 2h ago
Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
23 Jul 2026, 03:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Dr Reddy's Laboratories reported quarterly results that were weaker than expected. — Direct evidence of underperformance typically leads to immediate downward revisions of company valuation.
-0.60The company is experiencing supply disruptions for semaglutide. — Supply chain issues for a high-demand drug class directly threaten revenue growth and market share.
-0.50Brokerages have lowered their earnings forecasts for Dr Reddy's Laboratories. — Formal analyst downgrades often trigger institutional selling and lower the stock's price ceiling.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares declined following weaker-than-expected quarterly results and supply disruptions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
49m ago
